The key equity indices further extended gains and hit fresh record highs in mid-morning trade. The Nifty scaled above the 25,700 level. Auto shares advanced for the second trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, climbed 967.25 points or 1.17% to 84,151.28. The Nifty 50 index advanced 278.65 points or 1.10% to 25,701.35. The Sensex and Nifty clocked an all-time high of 84,240.50 and 25,691.15, respectively in mid-morning trade. Further, the Nifty Bank also hit a life high of 53,559.35. In the broader market, the S&P BSE Mid-Cap index added 0.61% and the S&P BSE Small-Cap index advanced 1.11%. The market breadth was strong. On the BSE, 2,460 shares rose and 1,275 shares fell. A total of 148 shares were unchanged. Buzzing Index : The Nifty Auto index added 1.68% to 26,342.10. The index advanced 2.08% in two trading sessions. Mahindra & Mahindra (up 4.23%), Maruti Suzuki India (up 2.47%), Eicher Motors (up 2.11%), Bosch (up 1.52%) and TVS Motor Company (up 1.35%), Hero MotoCorp (up 1.11%), Exide Industries (up 0.71%), Bajaj Auto (up 0.57%), Bharat Forge (up 0.49%) and Balkrishna Industries (up 0.28%) edged higher. On the other hand, Samvardhana Motherson International (down 1.43%), Apollo Tyres (down 0.02%) edged lower. Stocks in Spotlight : Abbott India fell 0.22%. The company said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, under the brand name Vonefi. Shalby rallied 3.39% after the company announced that it has received a license to operate a Bone Bank at Krishna Shalby Hospital. Global Markets: Asian stocks traded higher on Friday after Wall Street soared overnight following the Federal Reserve's outsized rate cut. Bank of Japan keeps key interest rate steady as it treads cautiously on normalizing policy. The Bank of Japan kept its benchmark interest rate steady at 'around 0.25%', the highest rate since 2008 at the conclusion of a two-day meeting Friday. Japan's economy has recovered moderately, the central bank said in its official statement, while acknowledging 'some weakness has been seen in part.' BOJ said the country's core inflation rate, which strips out fresh food prices will rise through fiscal year 2025. Japan's Core CPI, excluding volatile fresh food prices, increased by 2.8% year-on-year in August, reaching a 10-month high. This figure was in line with expectations and up from the 2.7% recorded in the previous month. A core reading that excludes both fresh food and energy prices, closely watched by the BOJ as a gauge of underlying inflation, rose to 2% in August from 1.9% in the prior month. Headline CPI inflation reached a 10-month high of 3% in August, up from 2.8% in the previous month. In China, the central bank maintained its benchmark lending rates, disappointing hopes for immediate policy support to bolster its struggling economy. China also kept its key lending rates steady, with the one-year loan prime rate at 3.35% and the five-year LPR at 3.85%. US stocks surged to new all-time highs on Thursday, as markets welcomed the Federal Reserve's aggressive interest rate cut to protect the labor market. The S&P 500 gained 1.7%, reaching 5,713.64, while the tech-heavy Nasdaq Composite Index jumped 2.5% to 18,013.98. The Fed on Wednesday reduced its key lending rate by 0.50%, opting for a larger cut after considering a quarter-point move. Powered by Capital Market - Live

Vonoprazan (PCAB or potassium competitive acid blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose. Current treatments for reflux esophagitis, a condition under the gastroesophageal reflux disease (GERD) umbrella, have several limitations including the need for multiple dosing for effectiveness, especially when the condition is severe. Vonoprazan, a first-of-its kind therapy, will help make it easier for patients to comply with their treatment and manage their condition better. This license will enable the company, a leader in the gut health space, to enhance access to this novel therapy to more patients across India. Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. The company's net profit jumped 41.1% to Rs 290.24 crore in Q1 FY24 as compared with Rs 205.64 crore in Q1 FY23. Revenue from operations was at Rs 1,479 crore in Q1 FY24, up 13.4% from Rs 1,304.12 crore reported in the same quarter previous year. Shares of Abbott India shed 0.51% to Rs 27,820.80 on the BSE.Powered by Capital Market - Live

Net profit of Abbott India rose 13.01% to Rs 328.01 crore in the quarter ended June 2024 as against Rs 290.24 crore during the previous quarter ended June 2023. Sales rose 5.32% to Rs 1557.61 crore in the quarter ended June 2024 as against Rs 1479.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1557.611479.00 5 OPM %25.1024.00 - PBDT455.59407.66 12 PBT437.22390.49 12 NP328.01290.24 13 Powered by Capital Market - Live

Abbott India will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live